Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment

Expert Systems celebrates a milestone in the clinical development of tivoxavir marboxil, a potential one-time influenza treatment.

Rhea-AI Summary

Expert Systems celebrates a milestone in the clinical development of tivoxavir marboxil, a potential one-time influenza treatment. Developed by Traws Pharma (NASDAQ: TRAW), tivoxavir showed positive topline Phase 1 safety and pharmacokinetic results, supporting its potential as a broad-spectrum flu treatment.

Expert Systems' AI-enabled drug discovery platform helped de-risk and fast-track tivoxavir's development. The study demonstrated good overall tolerability and a pharmacokinetic profile supporting one-time use for flu, including pandemic flu. Tivoxavir is positioned as a potential best-in-class inhibitor of drug-resistant influenza and bird flu viruses.

Phase 2a trials are set to begin in early 2025, aiming to evaluate tivoxavir's potential in reducing flu-related hospitalizations and mortality, especially in vulnerable populations.

Argus Session date unavailable

+4.26% session move Open Argus

Details

News Market Reaction – TRAW

The recorded move for TRAW in the trading session of this news was +4.26%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Oct. 10, 2024 /PRNewswire/ -- Expert Systems, a leader in combining human and artificial intelligence to accelerate drug discovery, celebrates a key milestone in the development of tivoxavir marboxil, a potential best-in-class inhibitor of the highly-conserved influenza protein, CAP-dependent endonuclease (CEN), intended for use across a broad range of flu viruses. Developed by Traws Pharma, Inc. (NASDAQ: TRAW), tivoxavir marboxil (tivoxavir) showed positive topline Phase 1 safety and pharmacokinetic results, supporting its potential as a one-time treatment for influenza.

Expert Systems' advanced AI-enabled drug discovery platform helped de-risk and fast-track tivoxavir's development from discovery to the clinic. Topline Phase 1 results demonstrated good overall tolerability and a pharmacokinetic profile that appears to support tivoxavir's potential use as a one-time treatment for flu, including pandemic flu. The successful outcome of this study positions tivoxavir as a potential best-in-class inhibitor of drug-resistant influenza and bird flu viruses. Phase 2a trials, set to begin in early 2025, will further evaluate tivoxavir's potential to help alleviate the public health burden associated with flu-related hospitalizations and mortality, especially in older adults and vulnerable populations.

"Tivoxavir's successful Phase 1 results are a testament to the power of our AI-enabled platform in accelerating the development of cutting-edge therapies," said Bill Farley, Chief Business Officer at Expert Systems. "Our platform helps de-risks the early stages of drug development, reducing time and costs while ensuring data-driven decisions. We are excited to support Traws Pharma in bringing this innovative flu treatment closer to market."

About Expert Systems, Inc.

Expert Systems, Inc., an advanced accelerator platform, is equipped with a comprehensive, hybrid AI-based system that covers the entire spectrum of preclinical drug discovery and early development phases. This includes target identification, virtual screening, non-clinical and clinical pharmacology, chemical liability assessment, and toxicology. Utilizing a unique combination of proprietary and public databases, Expert Systems employs specialized software tools to evaluate the intellectual property landscape and construct a competitive drug intelligence strategy to de-risk candidate selection for rapid transition from in silico to first-in-human trials. Expert Systems has been pivotal in establishing Seed and Series A companies, organizing and managing over 30 research and development programs across various financial investors and strategic partners in North America, Europe, and Australia. To learn more visit www.expertsystems.inc

Media Contact:

Bill Farley

CBO

bfarley@expertsystems.inc

View original content:https://www.prnewswire.com/news-releases/expert-systems-celebrates-milestone-in-clinical-development-of-tivoxavir-marboxil-potential-one-time-influenza-treatment-302273257.html

SOURCE Expert Systems, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the key findings from tivoxavir marboxil's Phase 1 trial for TRAW?

Tivoxavir marboxil's Phase 1 trial showed positive topline safety and pharmacokinetic results, demonstrating good overall tolerability and a pharmacokinetic profile that supports its potential use as a one-time treatment for influenza, including pandemic flu.

When will Traws Pharma (TRAW) begin Phase 2a trials for tivoxavir marboxil?

Traws Pharma (TRAW) is set to begin Phase 2a trials for tivoxavir marboxil in early 2025 to further evaluate its potential in reducing flu-related hospitalizations and mortality.

How did Expert Systems contribute to the development of tivoxavir marboxil for TRAW?

Expert Systems' AI-enabled drug discovery platform helped de-risk and fast-track tivoxavir marboxil's development from discovery to the clinic, reducing time and costs while ensuring data-driven decisions for Traws Pharma (TRAW).

What is the target of tivoxavir marboxil in treating influenza for TRAW?

Tivoxavir marboxil, developed by Traws Pharma (TRAW), is a potential best-in-class inhibitor of the highly-conserved influenza protein, CAP-dependent endonuclease (CEN), intended for use across a broad range of flu viruses.